Cellact Pharma GmbH
Records under this name other than the patents Cellact Pharma GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 5 of 5 · Back to Cellact Pharma GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,794,715 | Anti-TIRC7 antibodies in therapy of inflammatory diseases Term ended Term ended Aug 22, 2026 · From the USPTO record | Term ended | Term ended Aug 22, 2026 | From the USPTO record |
| US 9,096,654 | Peptides capable of modulating the function of TIRC7 Term ended Term ended Aug 17, 2026 · From the USPTO record | Term ended | Term ended Aug 17, 2026 | From the USPTO record |
| US 9,889,147 | Analogues of Etoposide for the Treatment of Tumours Lapsed on the fee record Ended Feb 13, 2026 · High confidence | Lapsed on the fee record | Ended Feb 13, 2026 | High confidence |
| US 9,827,261 | Etoposide and Prodrugs Thereof for Use in Targeting Cancer Stem Cells Lapsed on the fee record Ended Nov 28, 2025 · High confidence | Lapsed on the fee record | Ended Nov 28, 2025 | High confidence |
| US 10,806,745 | Analogues of Etoposide for the Treatment of Tumours Lapsed on the fee record Ended Oct 20, 2024 · Medium confidence | Lapsed on the fee record | Ended Oct 20, 2024 | Medium confidence |